You just read:

Glenmark Pharmaceuticals Announces Encouraging Phase 1 Results Supporting Biosimilarity Criteria for GBR 310 Compared to the Reference Product Omalizumab

News provided by

Glenmark Pharmaceuticals

Jul 25, 2018, 10:00 ET